Safety and Efficacy of Drug Combinations Against Trichuris Trichiura

Gaps in Helminth Control: Safety and Efficacy of Drug Combinations. Study on Trichuris Trichiura.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01050452

Enrollment

750

Registered

2010-01-15

Start date

2007-10-31

Completion date

2009-08-31

Last updated

2010-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parasitic Diseases

Brief summary

This randomised, controlled, double-blinded clinical study investigates the safety and efficacy of albendazole (ALB), mebendazole (MBD) and ivermectin (IVM) separately, and ALB and MBD each in combination with IVM in the treatment of Trichuris trichiura in children aged 5-14 years.

Interventions

DRUGalbendazole

albendazole (400 mg on dose)

DRUGmebendazole

mebendazole (500 mg one dose)

DRUGivermectin

ivermectin (200 microgram/kg body weight)

DRUGalbendazole + ivermectin

albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)

DRUGmebendazole + ivermectin

mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

5 Years to 15 Years

Healthy volunteers

Inclusion criteria

* Those who are enrolled in class one to six * Are infected with T. trichiura * Whose parent consent and who are willing to participate

Exclusion criteria

* Those with acute and chronic diseases other than T. trichiura * Those with a history of any serious adverse drug reactions

Design outcomes

Primary

Measure	Time frame
Record adverse reactions	6 weeks

Secondary

Measure	Time frame
Efficacy of treatment	6 weeks

Countries

Uganda

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026